Deirdre A Lane Selected Research

Rivaroxaban

6/2022	Effectiveness and Safety of Apixaban in over 3.9 Million People with Atrial Fibrillation: A Systematic Review and Meta-Analysis.
5/2015	Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis.
2/2015	Stroke risk reduction with oral anticoagulation using CHA2DS2-VASc in a Japanese AF population: A modeling analysis.
9/2014	Oral anticoagulants for stroke prevention in atrial fibrillation.
9/2013	Letter by Apostolakis et al regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts".
1/2013	Stroke prevention with oral anticoagulation therapy in patients with atrial fibrillation--focus on the elderly.
3/2012	Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Deirdre A Lane Research Topics

Disease

90	Atrial Fibrillation 09/2022 - 06/2006
78	Stroke (Strokes) 09/2022 - 06/2006
46	Hemorrhage 11/2022 - 06/2006
17	Hypertension (High Blood Pressure) 01/2022 - 04/2007
13	Ischemic Stroke 09/2022 - 10/2010
12	Heart Failure 11/2018 - 01/2011
11	Thromboembolism 01/2022 - 03/2012
7	Myocardial Infarction 01/2022 - 05/2005
7	Embolism (Embolus) 03/2017 - 07/2012
6	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 07/2008
6	Thrombosis (Thrombus) 07/2019 - 06/2006
6	Diabetes Mellitus 01/2019 - 02/2012
5	Acute Coronary Syndrome 01/2022 - 05/2011
4	Neoplasms (Cancer) 07/2022 - 04/2008
4	Venous Thromboembolism 01/2019 - 04/2015
4	Heart Valve Diseases (Valvular Heart Disease) 11/2018 - 05/2010
4	Cardiac Arrhythmias (Arrythmia) 12/2017 - 09/2013
3	Coronary Artery Disease (Coronary Atherosclerosis) 01/2022 - 07/2010
3	Dementia (Dementias) 01/2022 - 11/2016
3	Vascular Diseases (Vascular Disease) 11/2018 - 02/2015
3	Thyroid Diseases (Thyroid Disease) 05/2015 - 04/2008
3	Infections 05/2015 - 04/2008
3	Transient Ischemic Attack 12/2014 - 02/2012
2	Chronic Renal Insufficiency 01/2016 - 08/2012
2	Pre-Eclampsia (Preeclampsia) 04/2012 - 01/2012
1	Cerebral Hemorrhage 09/2022
1	Myocarditis (Carditis) 11/2021
1	Pericarditis 11/2021
1	COVID-19 01/2021
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2019
1	Psychotic Disorders (Schizoaffective Disorder) 03/2018
1	Peripheral Arterial Disease 03/2017
1	Overweight 07/2016
1	Obesity 07/2016
1	Coronary Disease (Coronary Heart Disease) 09/2015

Drug/Important Bio-Agent (IBA)

45	AnticoagulantsIBA 07/2022 - 06/2006
30	Warfarin (Coumadin)FDA LinkGeneric 01/2022 - 12/2008
30	Vitamin K FDA Link 01/2022 - 07/2009
12	Dabigatran FDA Link 06/2022 - 09/2010
10	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 11/2018 - 12/2008
9	apixabanIBA 06/2022 - 03/2012
8	N(4)-oleylcytosine arabinosideIBA 01/2022 - 05/2015
7	RivaroxabanIBA 06/2022 - 03/2012
6	Pharmaceutical PreparationsIBA 11/2022 - 04/2007
5	edoxabanIBA 12/2015 - 09/2014
5	von Willebrand FactorIBA 10/2013 - 01/2009
4	Clopidogrel (Plavix)FDA Link 11/2018 - 12/2008
4	idraparinuxIBA 09/2015 - 07/2011
4	AcenocoumarolIBA 09/2015 - 07/2011
4	ElectrolytesIBA 05/2015 - 04/2007
3	Biomarkers (Surrogate Marker)IBA 12/2020 - 07/2010
3	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2019 - 09/2010
2	omega-Chloroacetophenone (Mace)IBA 07/2022 - 01/2022
2	Antihypertensive Agents (Antihypertensives)IBA 01/2022 - 10/2009
2	Psychotropic Drugs (Psychoactive Drugs)IBA 01/2019 - 04/2015
2	Anti-Arrhythmia AgentsIBA 03/2017 - 02/2012
2	Thrombin FDA Link 07/2016 - 01/2011
2	CreatinineIBA 09/2015 - 05/2012
2	angiogeninIBA 04/2012 - 07/2011
2	mahuang-tangIBA 11/2009 - 11/2007
2	AngiotensinsIBA 12/2007 - 04/2007
2	Spironolactone (Aldactone)FDA LinkGeneric 12/2007 - 04/2007
1	boldenone undecylenate (Equipoise)IBA 09/2022
1	pleiotrophin (HARP)IBA 01/2022
1	TroponinIBA 01/2022
1	trans-crotonin (CTN)IBA 01/2022
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022
1	Anticonvulsants (Antiepileptic Drugs)IBA 01/2021
1	Antidepressive Agents (Antidepressants)IBA 01/2021
1	Antipsychotic Agents (Antipsychotics)IBA 01/2021
1	LipidsIBA 11/2020
1	idarucizumabIBA 01/2020
1	Biological ProductsIBA 01/2020
1	ElementsIBA 01/2020
1	Genetic Markers (Genetic Marker)IBA 01/2020
1	AntidotesIBA 06/2018
1	Soaps (Soap)IBA 03/2018
1	DiureticsIBA 08/2015
1	Digoxin (Digitek)FDA LinkGeneric 08/2015

Therapy/Procedure

62	Therapeutics 11/2022 - 06/2006
7	Secondary Prevention 01/2020 - 03/2011
4	Cardiac Rehabilitation 01/2022 - 01/2021
4	Patient Readmission 01/2022 - 01/2020
3	Drug Therapy (Chemotherapy) 11/2022 - 03/2017
3	Percutaneous Coronary Intervention 01/2019 - 05/2011
2	Vascular Surgical Procedures 11/2022 - 10/2022
2	Long-Term Care 01/2022 - 01/2021
2	Stents 07/2019 - 05/2011
2	Electric Countershock (Cardioversion) 01/2019 - 03/2017
2	Contraindications 09/2015 - 05/2010
2	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 07/2010 - 05/2005
1	Wearable Electronic Devices 05/2022
1	Critical Care (Surgical Intensive Care) 11/2021
1	Catheters 01/2021
1	Blood Pressure Monitors 07/2020
1	Polypharmacy 01/2020
1	Inappropriate Prescribing 01/2020
1	Catheter Ablation 01/2019
1	Diet Therapy (Therapy, Diet) 06/2018
1	Thrombectomy 03/2017